Shares in Aquestive Therapeutics (NSDQ:AQST) rose today after the company announced FDA approval for its Sympazan oral film for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.
The clobazam oral film is the first product of its kind to be approved by the FDA as a treatment for seizures associated with LGS, according to Aquestive. Clobazam has previously been available as a tablet and an oral suspension.
Get the full story at our sister site, Drug Delivery Business News.
The post Aquestive wins FDA nod for seizure oral film appeared first on MassDevice.